Franco Muggia

Summary

Affiliation: New York University School of Medicine
Country: USA

Publications

  1. pmc Treatment of liver metastases in patients with neuroendocrine tumors of gastroesophageal and pancreatic origin
    Ping Gu
    Department of Hematology and Medical Oncology, NYU Cancer Institute, New York, NY 10016, USA
    Int J Hepatol 2012:131659. 2012
  2. pmc Endocrine-responsive breast cancer: a 28-year Odyssey
    A West
    NYU School of Medicine, 550 First Avenue, New York, NY 10016, USA
    Ecancermedicalscience 5:237. 2011
  3. pmc Paraneoplastic hypercalcemia in clear cell ovarian adenocarcinoma
    S Lewin
    Department of Pediatrics, New York Presbyterian Weill Cornell Medical Center, New York, NY, USA
    Ecancermedicalscience 6:271. 2012
  4. ncbi request reprint 'BRCAness' and Its Implications for Platinum Action in Gynecologic Cancer
    Franco Muggia
    NYU Cancer Institute, New York University Langone Medical Center, 550 First Avenue, New, NY 10016, U S A
    Anticancer Res 34:551-6. 2014
  5. ncbi request reprint Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine
    Franco Muggia
    NYU Langone Medical Center, NY, USA
    Expert Opin Investig Drugs 21:403-8. 2012
  6. pmc XIII International Charles Heidelberger Symposium and 50 Years of Fluoropyrimidines in Cancer Therapy Held on september 6 to 8, 2007 at New York University Cancer Institute, Smilow Conference Center
    Franco M Muggia
    New York University Cancer Institute, NYU Langone Medical Center, New York, New York 10016, USA
    Mol Cancer Ther 8:992-9. 2009
  7. doi request reprint BRCA genes: lessons learned from experimental and clinical cancer
    F Muggia
    New York University Cancer Institute, New York, NY 10016, USA
    Ann Oncol 22:i7-10. 2011
  8. doi request reprint Conclusions: fruits of the convergence of laboratory, clinic and public
    F Muggia
    New York University Cancer Institute, New York 10016, USA
    Ann Oncol 22:i67-8. 2011
  9. doi request reprint Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer
    Franco Muggia
    Division of Medical Oncology, NYU Langone Cancer Institute, New York, NY 10016, USA
    Gynecol Oncol 112:275-81. 2009
  10. doi request reprint Postoperative intraperitoneal 5-fluoro-2'-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junction adenocarcinoma
    Deirdre J Cohen
    Division of Medical Oncology, New York University Cancer Center, NYU Medical Center, New York, NY, USA
    Ann Surg Oncol 19:478-85. 2012

Detail Information

Publications45

  1. pmc Treatment of liver metastases in patients with neuroendocrine tumors of gastroesophageal and pancreatic origin
    Ping Gu
    Department of Hematology and Medical Oncology, NYU Cancer Institute, New York, NY 10016, USA
    Int J Hepatol 2012:131659. 2012
    ..Future studies will likely further define the role of these agents in patients with carcinoid liver metastasis and pancreatic NET liver metastasis...
  2. pmc Endocrine-responsive breast cancer: a 28-year Odyssey
    A West
    NYU School of Medicine, 550 First Avenue, New York, NY 10016, USA
    Ecancermedicalscience 5:237. 2011
    ..In addition to the chronicity of disease, this history illustrates the expanding range of treatments available for endocrine-responsive breast cancer commensurate to our greater understanding of tumor biology...
  3. pmc Paraneoplastic hypercalcemia in clear cell ovarian adenocarcinoma
    S Lewin
    Department of Pediatrics, New York Presbyterian Weill Cornell Medical Center, New York, NY, USA
    Ecancermedicalscience 6:271. 2012
    ..This finding at presentation (possibly aggravated by oral calcium intake) led to discovery of a clear cell carcinoma of the ovary. The implications and pathophysiology of this association are reviewed...
  4. ncbi request reprint 'BRCAness' and Its Implications for Platinum Action in Gynecologic Cancer
    Franco Muggia
    NYU Cancer Institute, New York University Langone Medical Center, 550 First Avenue, New, NY 10016, U S A
    Anticancer Res 34:551-6. 2014
    ..The Cancer Genome Atlas analyses delineate the complexity of genomic alterations in ovarian cancer and other malignancies of Mullerian epithelial origin promising further refinements of the 'BRCAness' concept. ..
  5. ncbi request reprint Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine
    Franco Muggia
    NYU Langone Medical Center, NY, USA
    Expert Opin Investig Drugs 21:403-8. 2012
    ..Gemcitabine's action on signaling also provides a rational concept for combination with signal transduction pathways...
  6. pmc XIII International Charles Heidelberger Symposium and 50 Years of Fluoropyrimidines in Cancer Therapy Held on september 6 to 8, 2007 at New York University Cancer Institute, Smilow Conference Center
    Franco M Muggia
    New York University Cancer Institute, NYU Langone Medical Center, New York, New York 10016, USA
    Mol Cancer Ther 8:992-9. 2009
    This conference opened with Franco Muggia, host and principal organizer, thanking Joseph Landolph, co-Chair of the International Scientific Organizing Committee and its members (Franco Muggia, co-Chair, Max Costa, Steven Burakoff, Howard ..
  7. doi request reprint BRCA genes: lessons learned from experimental and clinical cancer
    F Muggia
    New York University Cancer Institute, New York, NY 10016, USA
    Ann Oncol 22:i7-10. 2011
    ..In addition to these models, the pathogenesis of high-grade serous disease derived from risk-reducing surgeries in mutation carriers has pointed to a role of mutations in p53 commonly encountered in tubal intraepithelial carcinomas...
  8. doi request reprint Conclusions: fruits of the convergence of laboratory, clinic and public
    F Muggia
    New York University Cancer Institute, New York 10016, USA
    Ann Oncol 22:i67-8. 2011
    ..It also reveals how the convergence of the laboratory, the clinic and the public across two continents is able to ignite discovery and its applications...
  9. doi request reprint Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer
    Franco Muggia
    Division of Medical Oncology, NYU Langone Cancer Institute, New York, NY 10016, USA
    Gynecol Oncol 112:275-81. 2009
    ..The status of DNA repair pathways may become relevant to response to platinums and to the treatment of ovarian cancer in general: repair inhibitors are under testing alone or in combination with cytotoxic drugs for cancer...
  10. doi request reprint Postoperative intraperitoneal 5-fluoro-2'-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junction adenocarcinoma
    Deirdre J Cohen
    Division of Medical Oncology, New York University Cancer Center, NYU Medical Center, New York, NY, USA
    Ann Surg Oncol 19:478-85. 2012
    ..However, locoregional recurrences remain high. Accordingly, we instituted this pilot/feasibility study, including intraperitoneal 5-fluoro-2'-deoxyuridine (IP FUDR) as part of the treatment...
  11. doi request reprint Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer
    Eleni Andreopoulou
    Department of Medical Oncology, Albert Einstein Cancer Center, Bronx, NY, USA
    Cancer Chemother Pharmacol 68:457-63. 2011
    ..Most ovarian cancers recur after first-line treatment. We studied the pharmacology, tolerability, and therapeutic potential of intraperitoneal (IP) topotecan, alone and with IP cisplatin...
  12. pmc A phase 2 study of oxaliplatin combined with continuous infusion topotecan for patients with previously treated ovarian cancer
    Stacey M Stein
    Division of Medical Oncology, Department of Medicine, Yale School of Medicine, New Haven, CT Division of Medical Oncology, Department of Medicine, and Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, New York University School of Medicine, New York, NY Beth Israel Cancer Center, Albert Einstein College of Medicine, NY New York University School of Medicine, New York, NY, Division of Biostatistics, Department of Population Health, New York University School of Medicine, New York, NY Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD and Department of Internal Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA
    Int J Gynecol Cancer 23:1577-82. 2013
    ..We sought to determine the efficacy and safety of oxaliplatin plus infusion topotecan in recurrent platinum-pretreated ovarian cancer...
  13. pmc Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study
    Howard Hochster
    Division of Medical Oncology, New York University School of Medicine, NYU Cancer Institute, NY 10016, USA
    Gynecol Oncol 108:500-4. 2008
    ..Topotecan 14-day infusion combined with cisplatin was highly active in ovarian cancer, but too myelosuppressive. We therefore sought to evaluate the feasibility of substituting oxaliplatin for cisplatin to improve safety...
  14. ncbi request reprint Weekly paclitaxel with intermittent imatinib mesylate (Gleevec): tolerance and activity in recurrent epithelial ovarian cancer
    Tamar Safra
    New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA
    Anticancer Res 30:3243-7. 2010
    ..Imatinib mesylate (IM, Gleevec), a potent PDGF/PDGFR tyrosine kinase inhibitor, affects stroma and vascular endothelial cells. Our study sought to determine the safety and activity of paclitaxel with an intermittent schedule of IM...
  15. ncbi request reprint Cisplatin with capecitabine: tolerance and activity in a phase I/II study preferentially enrolling patients with gastric cancer
    Jennifer Wu
    Divisions of Hematology and Medical Oncology, Department of Medicine, NYU Cancer Institute, NYU School of Medicine, 550 First Ave, BCD 556, New York, NY 1006, USA
    Anticancer Res 32:939-45. 2012
    ..We explored its tolerance and preliminary efficacy when given together with cisplatin in a phase I/II study preferentially enrolling gastric cancer patients...
  16. ncbi request reprint Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG study
    Howard S Hochster
    NYU School of Medicine and Cancer Institute, 160 East 34th Street, New York, NY 10016, USA
    Gynecol Oncol 100:324-9. 2006
    ..To determine the toxicity and efficacy of combined therapy with cisplatin and prolonged infusion topotecan as front line therapy in women with epithelial ovarian cancer...
  17. pmc Squamous cell carcinoma of the oral cavity in nonsmoking women: a new and unusual complication of chemotherapy for recurrent ovarian cancer?
    Timothy L Cannon
    NYU Cancer Institute, Division of Hematology Medical Oncology, 462 First Avenue, Building C D, New York, New York 10022, USA
    Oncologist 17:1541-6. 2012
    ..To describe occurrences of oral squamous cell carcinoma (SCC) in patients who had received long-term pegylated liposomal doxorubicin (PLD) for ovarian cancer...
  18. ncbi request reprint Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors
    Anna C Pavlick
    New York University School of Medicine, New York University Cancer Institute, New York, NY, USA
    Cancer Chemother Pharmacol 64:803-10. 2009
    ..We designed a phase I study to achieve tolerable doses and schedules of bryo and cisplatin in combination and in this sequence...
  19. pmc A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: a feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: a Gynecologic Oncology Group study
    Amy D Tiersten
    New York University Cancer Institute, New York, NY 10016, USA
    Gynecol Oncol 118:303-7. 2010
    ..We also investigated the toxicities including the percentage of patients with grade 2 or greater peripheral neurotoxicity and the clinical response of this regimen...
  20. ncbi request reprint Neoadjuvant chemotherapy, surgery, and adjuvant intraperitoneal chemotherapy in patients with locally advanced gastric or gastroesophageal junction carcinoma: a phase II study
    Elliot Newman
    Department of Surgery, New York University School of Medicine, and the NYU Cancer Institute, New York, NY, USA
    Semin Oncol 32:S97-100. 2005
    ..The data suggest that an approach consisting of systemic induction therapy, curative surgery with high R0 resection rates, and IP adjuvant therapy has acceptable toxicity and encouraging survival outcomes...
  21. doi request reprint BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin
    Tamar Safra
    NYU Cancer Institute, 160 34th St, New York, NY 10016, USA
    Mol Cancer Ther 10:2000-7. 2011
    ..Tumors arising in a background of defective BRCA function are more sensitive than other EOCs to DNA-damaging agents such as PLD, even after acquiring platinum resistance...
  22. pmc Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival
    Sylvia Adams
    Department of Radiation Oncology, New York University School of Medicine, 160 E 34th Street, New York, NY, 10016, USA
    Breast Cancer Res Treat 124:723-32. 2010
    ..In conclusion, pathologic response to concurrent paclitaxel-radiation translated into superior DFS and OS. Half of the patients with HR negative tumors achieved a pathologic response...
  23. pmc Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences?
    Maryann Kwa
    NYU Clinical Cancer Center, 550 First Avenue, New York, NY 10016, USA
    Oncologist 17:1534-40. 2012
    ..To document the frequency and contributing factors to the emergence of CKD, we initiated a retrospective review at two institutions...
  24. ncbi request reprint Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer
    Eleni Andreopoulou
    Department of Medical Oncology, New York University Medical Center, New York, NY 10016, USA
    Clin Breast Cancer 7:690-6. 2007
    ..This open-label, prospective, phase II trial assessed the safety and efficacy of this regimen, with cardiac tolerance as the principal focus...
  25. ncbi request reprint A phase I and pharmacokinetic study of docetaxel combined with Doxil (pegylated liposomal doxorubicin) without and with granulocyte colony stimulating factor
    Anna C Pavlick
    Division of Medical Oncology, Department of Medicine, Kaplan Cancer Center, NYU Cancer Institute, New York University Medical Center, 462 First Avenue, BCD Room 556, New York, NY 10016, USA
    Anticancer Drugs 15:119-25. 2004
    ..Our observations should provide evidence for phase II studies of this combination in patients with breast cancer and other anthracycline/taxane-sensitive cancers...
  26. ncbi request reprint Fatal hepatitis B reactivation due to everolimus in metastatic breast cancer: case report and review of literature
    Eleonora Teplinsky
    New York University Cancer Institute, New York, NY, 10016, USA
    Breast Cancer Res Treat 141:167-72. 2013
    ..Clinicians and patients should be aware of this rare but fatal complication prior to everolimus use, and a detailed history, screening for hepatitis B and prophylactic antiviral treatment should be considered. ..
  27. pmc Loss of p27KIP1 expression in fully-staged node-negative breast cancer: association with lack of hormone receptors in T1a/b, but not T1c infiltrative ductal carcinoma
    Deepu Mirchandani
    New York University School of Medicine and NYU Cancer Institute, New York, NY, USA
    Anticancer Res 31:4401-5. 2011
    ..We examined by IHC the association between nuclear p27(KIP1) expression and hormone receptor status in T1N0M0 breast cancer...
  28. ncbi request reprint Defining risks of taxane neuropathy: insights from randomized clinical trials
    David Kudlowitz
    New York University School of Medicine and Cancer Institute, New York, New York 10016, USA
    Clin Cancer Res 19:4570-7. 2013
    ..In addition, the differences highlighted may lead to greater insight into drug and basic host factors (such as age, sex, and ethnicity) contributing to axonal injury from taxanes...
  29. ncbi request reprint Ovarian cancer in BRCA mutation carriers: improved outcome after intraperitoneal (IP) cisplatin
    Maryann Kwa
    New York University Medical Center, NYU Cancer Institute, New York, NY, USA
    Ann Surg Oncol 21:1468-73. 2014
    ..We analyze our previously published intraperitoneal (IP) studies in relation to BRCA mutation status and update their outcomes...
  30. doi request reprint Continuous-infusion topotecan and erlotinib: a study in topotecan-pretreated ovarian cancer assessing shed collagen epitopes as a marker of invasiveness
    Eiran Warner
    Beth Israel Medical Center, New York, New York, USA
    Oncologist 19:250. 2014
    ..We assessed the activity of such a regimen in ovarian cancer patients previously failing bolus topotecan. Assay for shed collagen epitopes recognized by antibody HU177 during treatment explored its ability to reflect tumor invasion...
  31. ncbi request reprint Concurrent radiotherapy, paclitaxel and dose escalating carboplatin in the treatment of cervical cancer--a phase I study
    Daniela Addeo
    New York University, Department of Radiation Oncology, New York, NY 10016, USA
    Anticancer Res 28:3143-6. 2008
    ..This study was designed to determine the feasibility and toxicity of concomitant administration of RT with twice per week paclitaxel and carboplatin...
  32. ncbi request reprint A pilot study of letrozole for one year in women at enhanced risk of developing breast cancer: effects on mammographic density
    Julia Smith
    Department of Medicine Oncology and NYU Cancer Institute, New York University School of Medicine, New York, NY 10016, USA
    Anticancer Res 32:1327-31. 2012
    ..To address safety concerns and seek enhanced efficacy, studies of new chemopreventive agents using mammographic density as a surrogate end point are attractive...
  33. doi request reprint Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma
    Jennifer Wu
    Department of Medical Oncology, NYU School of Medicine, New York, NY, USA
    Invest New Drugs 28:670-6. 2010
    ..Darinaparsin is a novel organic arsenic that reaches higher intracellular concentration with decreased toxicity compared to inorganic arsenic. We conducted a multi-center phase II study with darinaparsin in patients with advanced HCC...
  34. ncbi request reprint Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma
    Patrick A Ott
    Division of Medical Oncology, New York University Cancer Institute, New York University School of Medicine, New York, NY 10016, USA
    Chemotherapy 55:221-7. 2009
    ..This phase II study evaluated the efficacy and tolerability of dacarbazine in combination with thalidomide in metastatic melanoma patients...
  35. ncbi request reprint A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer
    Michael V Seiden
    The Division of Medical Oncology, New York University, New York, NY 10016, USA
    Gynecol Oncol 93:229-32. 2004
    ..To determine the safety and efficacy of a novel topoisomerase I inhibitor, liposomal lurtotecan, in patients with topotecan resistant ovarian cancer...
  36. ncbi request reprint Neoadjuvant chemotherapy with CPT-11 and cisplatin downstages locally advanced gastric cancer
    Elliot Newman
    Department of Surgery, New York University School of Medicine, New York, New York 10016, USA
    J Gastrointest Surg 6:212-23; discussion 223. 2002
    ..We conclude that CPT-11-based neoadjuvant therapy downstages locally advanced gastric cancer. Further follow-up is necessary to determine the ultimate impact of this combination therapy on recurrence and survival...
  37. doi request reprint A pharmacokinetic evaluation of topotecan as a cervical cancer therapy
    Fernanda Musa
    NYU Langone Medical Center, Department of Obstetrics and Gynecology, NY, USA
    Expert Opin Drug Metab Toxicol 9:215-24. 2013
    ..As a topoisomerase I (topo I) inhibitor, its activity is predicted to be schedule-dependent and potentiated in a schedule-dependent manner by its interaction with DNA damaging agents...
  38. ncbi request reprint Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer
    Howard Hochster
    NYU School of Medicine, 160 East 32nd St, New York, NY 10016, USA
    J Clin Oncol 21:2703-7. 2003
    ..To determine the activity of biweekly oxaliplatin, combined with weekly bolus fluorouracil (FU) and low-dose leucovorin (LV) chemotherapy (bFOL), as first-line therapy for patients with metastatic colorectal cancer...
  39. ncbi request reprint Emerging treatments for ovarian cancer
    Franco Muggia
    Division of Medical Oncology, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA
    Expert Opin Emerg Drugs 8:203-16. 2003
    ..Targeted' drug trials, in contrast to trials studying cytotoxic drug analogues, currently represent only a minor portion of clinical trials in ovarian cancer...
  40. ncbi request reprint Epidermal growth factor receptor inhibitors for the treatment of epithelial ovarian cancer
    Stephanie V Blank
    Department of Obstetrics and Gynecology NYU School of Medicine, NY 10016, USA
    Oncology (Williston Park) 19:553-9; discussion 560-2, 567. 2005
    ..It is hoped that data from these and other studies will help investigators to understand more clearly the biology of ovarian cancer and to delineate the role of EGFR inhibitors in the management of ovarian cancer...
  41. ncbi request reprint Clinical features of taxane neuropathy
    David Kudlowitz
    aDepartment of Medicine, NYU Langone Medical Center bDepartment of Oncology, NYU Clinical Cancer Institute, New York, New York, USA
    Anticancer Drugs 25:495-501. 2014
    ..In addition, case vignettes illustrate the range of clinical manifestations of this toxicity during taxane administration...
  42. ncbi request reprint Novel taxanes
    Franco Muggia
    NYU Cancer Institute, New York, New York, USA
    Anticancer Drugs 25:593-8. 2014
    ..Through this mechanism, novel formulations increase cytotoxicity, improve specificity, and create possibilities for drug enhancement. ..
  43. ncbi request reprint Ovarian cancer: a brief historical overview of intraperitoneal trials
    Maryann Kwa
    NYU Cancer Institute, New York University Medical Center, New York, NY, USA
    Ann Surg Oncol 21:1429-34. 2014
    ..In this article, we highlight the key trials and recent directions in IP therapy of ovarian cancer and briefly discuss another approach to the delivery of IP chemotherapy, known as hyperthermic intraperitoneal chemotherapy. ..
  44. ncbi request reprint Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial
    Silvia C Formenti
    Kaplan Comprehensive Cancer Center, New York University School of Medicine, New York, NY, USA
    J Clin Oncol 21:864-70. 2003
    ..We investigated the safety and efficacy of primary twice-weekly paclitaxel and concurrent radiation (RT) before modified radical mastectomy followed by adjuvant doxorubicin-based chemotherapy...
  45. ncbi request reprint Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study
    Farr Nezhat
    Mount Sinai School of Medicine, New York, NY 10029, USA
    Gynecol Oncol 93:144-8. 2004
    ..The current study was conducted to evaluate this therapeutic approach in patients with recurrent or advanced-stage cervical carcinoma...